PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.03 (17.647%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Possible Acquisition and Suspension of Trading

16 Sep 2016 13:03

RNS Number : 0897K
Levrett PLC
16 September 2016
 

Levrett plc ("Levrett" or the "Company")

 

Possible Acquisition and Suspension of Trading

 

The Directors of Levrett are pleased to inform shareholders that the Company has signed a non-binding letter of intent to acquire the entire issued share capital of Nuformix Limited, a UK incorporated company operating in the cocrystal technology sector, for new shares in the Company (the "Acquisition").

 

The Acquisition is subject, inter alia, to the completion of due diligence, documentation and compliance with all regulatory requirements, including the Listing and Prospectus Rules and, as required, the Takeover Code.

 

The Company intends to convene a General Meeting as soon as practicable in order to seek the shareholder approvals necessary to pursue this opportunity. It should also be noted that if the Acquisition proceeds, further shareholder consent may also be required including to deal with any applicable requirements of the Takeover Code.

 

Suspension and Application for Listing

 

The Acquisition, if it proceeds, will constitute a Reverse Takeover under the Listing Rules since, inter alia, in substance it will result in a fundamental change in the business of the issuer.

 

As the Acquisition will constitute a Reverse Takeover under the Listing Rules, trading in the Company's ordinary shares have been suspended (pursuant to Listing Rule 5.3.1) with immediate effect pending the publication of a prospectus and the application for the enlarged Company to have its ordinary shares admitted to the Official List and to trading on the main market for listed securities of the London Stock Exchange.

 

The Company is working on the preparation of a prospectus in relation to the Acquisition and will, in due course, be making application for the enlarged Company to have its ordinary shares admitted to the Official List and to trading on the main market for listed securities of the London Stock Exchange.

 

The Company will update shareholders as the matter progresses.

 

Enquiries:

 

Levrett Plc

Pascal Hughes, CEO

 

+44 (0) 20 7183 4342

Whitman Howard Limited

Niall Baird / Nick Lovering

 

+44 (0) 20 7659 1234

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQGMGMLZVGGVZM
Date   Source Headline
15th Jan 202012:43 pmRNSAmendment to Notice
10th Jan 202011:45 amRNSIssue of Equity
8th Jan 20208:17 amRNSHolding(s) in Company
24th Dec 20197:00 amRNSHalf-year Report
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:36 pmRNSPrice Monitoring Extension
25th Nov 20197:00 amRNSUpdate and Placing Announcement
28th Oct 20192:05 pmRNSSecond Price Monitoring Extn
28th Oct 20192:00 pmRNSPrice Monitoring Extension
28th Oct 20198:30 amRNSIssue of Equity
25th Oct 201911:11 amRNSStatement re. Share Price Movement
25th Oct 20199:05 amRNSSecond Price Monitoring Extn
25th Oct 20199:00 amRNSPrice Monitoring Extension
20th Sep 20192:05 pmRNSSecond Price Monitoring Extn
20th Sep 20192:00 pmRNSPrice Monitoring Extension
10th Sep 20194:49 pmRNSAGM Results
10th Sep 20197:00 amRNSDirectorate Change
9th Sep 20197:00 amRNSEbers Cannabinoid Collaboration Update
6th Sep 20197:30 amRNSAppointment of Dr Muhunthan Thillai
4th Sep 20197:30 amRNSHolding(s) in Company
1st Aug 20199:30 amRNSAnnual Financial Report
29th Jul 20197:00 amRNSHolding(s) in Company
18th Jul 20197:00 amRNSFinal Results
7th Jun 20197:00 amRNSHolding(s) in Company
6th Jun 20197:00 amRNSHolding(s) in Company
30th May 201911:05 amRNSSecond Price Monitoring Extn
30th May 201911:00 amRNSPrice Monitoring Extension
30th May 20197:01 amRNSPositive Results for NXP001 Clinical Trial
28th May 20197:00 amRNSHolding(s) in Company - Amendment
24th May 20197:30 amRNSHolding(s) in Company
24th May 20197:00 amRNSLoan Conversion
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
15th May 20194:40 pmRNSSecond Price Monitoring Extn
15th May 20194:35 pmRNSPrice Monitoring Extension
15th May 20197:00 amRNSNuformix Achieves 2nd NXP001 Development Milestone
10th May 20199:00 amRNSPrice Monitoring Extension
8th May 20197:30 amRNSHolding(s) in Company
9th Apr 20197:00 amRNSStrategic Cannabinoid Agreement
5th Apr 20197:00 amRNSNotification Major Share Interests
22nd Mar 20197:00 amRNSNuformix Commences NXP001 Clinical Trial
27th Feb 20197:00 amRNSMHRA approval for NXP001
20th Feb 20196:16 pmRNSHolding(s) in Company
20th Dec 20187:00 amRNSUnaudited Half Year Results
3rd Dec 20187:00 amRNSReports Results from Novel IPF Pre-Clinical Trial
27th Nov 20187:00 amRNSExpansion of NXP001 Agreement & Milestone Payment
28th Sep 201810:09 amRNSDirector/PDMR Shareholding
28th Sep 20187:00 amRNSAdditional New NXP002 Patent Filing
19th Sep 20182:33 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.